Atty. Docket No.:

27053/2062

PATENT

THE UNITED STATES PATENT AND TRADEMARK OFFICE

opplication of:

Hayley Zen

Serial No.:

10/674,148

Filed:

September 29, 2003

Entitled:

"5-benzoylamino-1,3-dioxacyclanes,

the method for preparing the same,

and their use as PKC inhibitor"

Examiner:

Not Yet Assigned

Group Art Unit:

Not Yet Assigned

Conf. No.:

Not Yet Assigned

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8a

I hereby certify that this correspondence (and any paper or fee referred to as being enclosed) is being deposited with the United States Post Office as First Class Mail on the date indicated below in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Brenda M. Woods

Name of Person Mailing Paper

Signature of Person Mailing Paper

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Enclosed for filing in the above-identified patent application, please find the following documents:

- 1. Information Disclosure Statement;
- 2. Form PTO-1449;
- 3. Copies of Cited References; and
- Return Post Card. 4.

The Commissioner for Patents is hereby authorized to charge any additional fees or credit any overpayment in the total fees to Deposit Account No. 16-0085, Reference No. 27053/2062. A duplicate of this transmittal letter is enclosed for this purpose.

Respectfully submitted,

Date:

December /, 2003

Name: Mark J. FitzGerald

Registration No.: 45,928 Palmer & Dodge LLP 111 Huntington Avenue Boston, MA 02199-7613

Tel: 617-239-0100

DEC 0 4 7000 ELE

Atty. Docket No.:

27053/2062

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:

Hayley Zen

Serial No.:

10/674,148

Filed:

September 29, 2003

Entitled:

"5-benzovlamino-1,3-dioxacyclanes,

the method for preparing the same,

and their use as PKC inhibitor"

Examiner:

Not Yet Assigned

Group Art Unit:

Not Yet Assigned

Conf. No.:

Not Yet Assigned

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8a

I hereby certify that this correspondence (and any paper or fee referred to as being enclosed) is being deposited with the United States Post Office as First Class Mail on the date indicated below in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Brenda M. Woods

Name of Person Mailing Paper

Signature of Person Mailing Paper

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§§ 1.56, 1.97 AND 1.98

Dear Sir:

In accordance with the duty of disclosure under 37 CFR § 1.56, Applicant submits this Information Disclosure Statement pursuant to 37 CFR §§ 1.97 and 1.98 in the above-identified application for consideration by the Patent Office.

A listing of the cited documents is also enclosed, as well as, for the Examiner's convenience, copies of the documents in the list.

Pursuant to CFR § 1.97(b)(3), because this Statement is being submitted before the first Office Action on the merits, no fee is required.

Applicant does not intend to represent that any of the documents submitted herein are material prior art to this invention or that the list represents an exhaustive search of documents related to this invention.

Applicant respectfully requests that the documents submitted herein be considered and made of record in this application.

Date:

December / . 2003

Respectfully submitted,

Man 1

Name: Mark J. FitzGerald Registration No.: 45,928 Palmer & Dodge LLP 111 Huntington Avenue Boston, MA 02199-7613

Tel: 617-239-0100

A TABLE	8) E								
USPTO Form 1449 U.S. Department of Commerce Patent and Trademak Office UNFORMATION DISCLOSURE STATEMENT				Attorney Docket No. 27053/2062		Serial No. 10/674,148			
									Applicant(s):. Hayley Zen
				Filing Date: September 29, 2003			Group: Not Yet Assigned		
				U.S. PAT	TENT DO	OCUMENTS			
Examiner Initial		Patent No.	Date	Name	ame Class Subclass Filing Date (if appropriat				
						<u> </u>			
FOREIG	N PATE	NT DOCUMENTS	_						
Examiner Initial		Document No.	Publication Date	Country	Class	Subclass	Translation		
					<u> </u>		YES	NO	
OTHER I	DOCUM	ENTS (including Auth	nor, Title, Date, Pertin	nent Pages, etc.)					
•	1.	Wender, P.A. et al., (1998), "The chemistry-medicine continuum: Synthetic, computer, spectroscopic and biological studies on new chemotherapeutic leads", <i>Pure. & Appl. Chem.</i> , 70(3):539-546.							
·	2.	Lee, J. et al., (1996), "Conformationally Constrained Analogues of Diacylglycerol. 11. Ultrapotent Protein Kinase C Ligands Based on a Chiral 5-Disubstituted Tetrahydro-2-furanone Template", J. Med. Chem., 39:29-35.							
	3.	Lee, J. et al., (1996), "Conformationally Constrained Analogues of Diacylglycerol. 12. Ultrapotent Protein Kinase C Ligands Based on a Chiral 4,4-Disubstituted Heptono-1,4-lactone Template", <i>J. Med. Chem.</i> , 39:36-45.							
EXAMINER					DATE CC	DATE CONSIDERED			
*EXAMINER: next communica	Initial if referen	nce considered, whether or not citation ant.	n is in conformance with MPEP 609	9. Draw line through citation if not in	conformance an	d not considered.	. Include copy of this	form with	

**Copies of references not provided at the time of this submission.